This study uses fecal microbiota transplant (FMT) to correct gut microbiome dysbiosis prior to and during standard-of-care neuroblastoma treatment

Patients with neurobastoma and concurrent dysbiosis showing a bifidobacteria-bacteroides gap will undergo fecal microbiota transplant as an adjunctive to standard-of-care oncology treatment.

Inclusion Criteria:

• willingness of parent/guardian to sign ICF
• diagnosis of neuroblastoma
• dysbiosis of the gut microbiome

Exclusion Criteria:

• parent/guardian unwilling to sign ICF
• dysbiosis does not show a bifidobaceteria-bacteroides gap
• severely abnormal screening lab values